8 results about "Acute cardiac failure" patented technology

The present invention discloses the use of a compound of formula I sertaconazole or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for preventing or treating oxidative stress-related cardiovascular diseases. Specifically, the present invention relates to the use of said compound in the preparation of a medicament for preventing or treating oxidative stress-related vascular diseases, including but not limited to acute coronary syndrome, alcoholic heart dysfunction, hypoxic pulmonary arterial hypertension, heart failure, drug-induced cardiotoxicity and stroke, especially acute heart failure.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof:wherein each symbol means the same as that described in the specification.

Embodiments disclosed herein establish relationships between changes in cardiovascular indicators and drug combinations. These relationships are established by tracking causal chains described by linear relationships, from drug combinations to cardiovascular parameters and from cardiovascular parameters to cardiovascular indicators, by measuring the direction and sensitivity of hemodynamic changes caused by changes in cardiovascular parameters (resulting from drug administration). Some embodiments also model myocardial oxygen consumption, which cannot be directly measured, and establish relationships between hemodynamic changes in myocardial oxygen consumption and changes in one or more cardiovascular parameters. Because these embodiments qualitatively and quantitatively establish causal chains from drugs to cardiovascular indicators, they support clinical decision-making, thereby reducing the level of mere guesswork and uncertainty in determining the optimal drug combination for patients with acute heart failure.

The present invention relates to an anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment that binds to adrenomedullin, for use in congestion therapy in a patient with congestive hypertension; heart failure, in particular acute heart failure; wherein said anti-ADM antibody or anti-ADM fragment binds to the N-terminal portion (aa 1 to 21) of adrenomedullin YRWSMNNFWGLRSFGCRFGTC (SEA ID NO. 22), and wherein said patient is resistant to diuretics or does not respond to diuretic therapy.

This disclosure provides methods and devices for evaluating a patient's heath by assessing the patient's thermoregulatory response to heat. For example, methods include applying heat to patient skin and measuring rate of temperature change. If the rate of temperature change exceeds a pre-determined threshold, the patient can be identified as suffering from acute heart failure.

The invention belongs to the field of cardiovascular diagnosis, and particularly relates to a cardiovascular diagnosis and risk early warning system and method based on millimeter wave radar monitoring. Synchronous non-inductive monitoring of multi-dimensional parameters such as the body fluid retention index, the heart rate variability, the arrhythmia and the respiratory event of the user during night sleep is achieved. According to the system, through an original multi-mode risk feature incidence matrix and an artificial intelligence time sequence model, the core pathophysiological and physiological index of dynamic balance of body fluid is deeply fused with other physiological signals, and a specific high-risk coupling mode is identified; therefore, early-stage and high-specificity risk early warning of acute myocardial infarction, ischemic cerebral apoplexy and acute heart failure decompensation is realized; according to the invention, the problems of lack of pathophysiological depth and insufficient specificity in the existing early warning technology are solved, and a revolutionary active health management tool is provided for cardiovascular and cerebrovascular high-risk groups.

The invention relates to the technical field of biological medicines, in particular to application of a cream globule epidermal growth factor 8 in preparation of a medicine for treating acute heart failure. The milk fat globule epidermal growth factor 8 or the functional fragment, the modified derivative, the expression promoter and the recombinant protein thereof are used for preparing the acute heart failure treatment medicine, myocardial cell systolic dysfunction can be relieved by inhibiting the increase of the acetylation modification level of intracellular tubulin, and then acute heart failure is treated. Particularly, the acute heart failure without basic heart disease can be quickly improved.